MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2014-08-08
Last Posted Date
2014-08-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02211963

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 14332 CL
Drug: Placebo
First Posted Date
2014-08-08
Last Posted Date
2014-08-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
53
Registration Number
NCT02211989

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-08-08
Last Posted Date
2014-08-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02211924

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 44847 tablet, high dose
Drug: BI 44847 solution, low dose
Drug: BI 44847 suspension, high dose
Drug: BI 44847 tablet, low dose
Other: high fat breakfast
First Posted Date
2014-08-08
Last Posted Date
2014-08-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
25
Registration Number
NCT02211937

Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects

Phase 1
Completed
Conditions
Healthy
First Posted Date
2014-08-08
Last Posted Date
2014-08-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6
Registration Number
NCT02211885

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: BI 2536 BS, intravenous
First Posted Date
2014-08-08
Last Posted Date
2014-08-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
63
Registration Number
NCT02211872

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBR 796 BS
Drug: Placebo
Other: high fat breakfast
First Posted Date
2014-08-07
Last Posted Date
2014-08-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02211157

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBR 796 BS, low dose
Drug: Placebo
Drug: BIBR 796 BS, high dose
Drug: Lipopolysaccharide
First Posted Date
2014-08-07
Last Posted Date
2014-08-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02211170

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: BIBR 796 BS
First Posted Date
2014-08-07
Last Posted Date
2014-08-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
120
Registration Number
NCT02211144

Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors

Phase 1
Terminated
Conditions
Head and Neck Neoplasms
Interventions
First Posted Date
2014-08-06
Last Posted Date
2014-08-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3
Registration Number
NCT02209701
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy